A comparison of different surfactants on foam stability in foam sclerotherapy in vitro

Bai, Taoping; Liu, Yuqiu; Liu, Jiche; Chen, Yu; Jiang, Wentao; Fan, Yubo

doi:10.1016/j.jvs.2018.02.033

Cited by 20 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sclerosant foam stability is influenced by various factors, including gas formulation, 17 type and concentration of sclerosant, liquid-gas ratio, 18 viscosity, 19 number of pump cycles and different surfactants, 20 etc. Due to its poor stability, foam collapses rapidly, resulting in a short contact time and a limited area of contact between the sclerosant and the vascular endothelial cells.…”

Section: Discussionmentioning

confidence: 99%

The role of hyaluronic acid in polidocanol foam: An in vitro study

Liu

Xuanxuan

et al. 2022

Phlebology

View full text Add to dashboard Cite

Objective To study the role of hyaluronic acid (HA) in polidocanol (POL) foam. Methods The dose-dependent effect of HA-POL on cultured human umbilical vein endothelial cells (HUVECs) as well as foam stability was evaluated by measuring optical density (OD) values and foam half-life time (FHT), respectively. An in vitro model was utilized for estimating the foam blood-displacement capacity by adopting maximum displacement distance (MDD) and displacement time. A comparison of foam viscosity was also carried out. Results The OD values of HUVECs treated with HA first increased and then decreased with the growing dosage of HA while cells treated with HA-POL died. Both FHT and displacement time were prolonged statistically with a gradually enhanced foam viscosity. As to MDD, there were no significant differences. Conclusions HA was found to promote HUVECs proliferation slightly, but this was almost negligible when compared to the cell-killing capacity of 1% POL. The viscosity of POL foam was enhanced by HA indicating its positive correlation with both stability and displacement capacity of POL foam.

show abstract

Section: Discussionmentioning

confidence: 99%

The role of hyaluronic acid in polidocanol foam: An in vitro study

Liu

Xuanxuan

et al. 2022

Phlebology

View full text Add to dashboard Cite

show abstract

“…Foam stability can be determined by foam half-life, which is the time required to reach half of its initial volume after foam production. A higher half-life time indicates preferred stability ( Bai et al, 2019 ). As discussed previously, the homogenizer was used for foam formation ( Parsa et al, 2019 ).…”

Section: Methodsmentioning

confidence: 99%

Atorvastatin-loaded emulsomes foam as a topical antifungal formulation

Eita

Makky

Anter

et al. 2022

International Journal of Pharmaceutics: X

View full text Add to dashboard Cite

“…The experimental data were examined on videotape to ensure accuracy. The recorded data to elucidate bleomycin polidocanol foam decay and stability included (i) the drainage rate (equal to the drainage liquid volume divided by the drug volume) 21 and corresponding time that described different foam drainage processes; (ii) the half life (the time needed for half of the original volume of sclerosing solution to revert to liquid state); 24 and (iii) the drainage time (the time when a liquid phase appears and could be observed in the syringe). 24,25,28 Because of foam instability, both experimental groups and control groups were repeated 10 times to ensure the comparability of the experiment results, and repeated processes were carried out under the same conditions.…”

Section: Foam Stability Measurementmentioning

confidence: 99%

Bleomycin Polidocanol Foam (BPF) Stability – In Vitro Evidence for the Effectiveness of a Novel Sclerosant for Venous Malformations

Sun

Yang

et al. 2020

European Journal of Vascular and Endovascular Surgery

View full text Add to dashboard Cite

WHAT THIS PAPER ADDSThis study describes an in vitro investigation into the stability of a novel sclerosant, bleomycin polidocanol (BPF), for venous malformation sclerotherapy. The efficacy of BPF in clinical experience suggests that BPF sclerotherapy is a highly efficient and safe therapy. The foam decay process, foam drainage rate, half life and the foam diameters and uniformity are given in this study. This is probably the first in vitro investigation of BPF. This study shows that foam stability is related to bleomycin and polidocanol concentrations; a small amount of bleomycin resulted in improved stability of BPF.Objective: This study investigated the in vitro stability of a novel sclerosant, bleomycin polidocanol foam (BPF), for venous malformation (VM) sclerotherapy. Methods: The study was designed with control groups treated with polidocanol (0.5%, 1%, and 3%) only. The experimental groups included 21 BPFs, which was made by dissolving bleomycin at seven different concentrations (0.1%e1.5%) in polidocanol (0.5%, 1%, and 3%). The Tessari method was used to prepare sclerosant foam with a liquid:gas ratio of 1:4 at room temperature in vitro. The foam stability was measured for each group. The decay process, one component of foam stability, was recorded with a camera. Foam decay process experiments were performed 10 times per group. The stability indices included drainage rate, drainage time, half life, and microscopic measurement of the foams (mean bubble diameter, minimum and maximum bubble diameters, wall thickness, and bubble diameter distribution). Results: Compared with the control groups, the half lives of BPFs mainly increased significantly with the addition of bleomycin (p < .001). BPF with 3% polidocanol and 0.1% bleomycin recorded the highest half life (246 AE 1.6 sec), and this group also achieved the smallest bubble diameter and wall thickness (69.9 mm and 5.80 mm) among the experimental groups. For the same polidocanol concentration, the bubble diameter and wall thickness increased when bleomycin was added. Conclusion: Bleomycin concentrations account for different BPF stability. BPF stability mainly increased significantly with the addition of a small amount of bleomycin but this advantage was no longer apparent with increasing bleomycin dose.

show abstract

A comparison of different surfactants on foam stability in foam sclerotherapy in vitro

Cited by 20 publications

References 27 publications

The role of hyaluronic acid in polidocanol foam: An in vitro study

The role of hyaluronic acid in polidocanol foam: An in vitro study

Atorvastatin-loaded emulsomes foam as a topical antifungal formulation

Bleomycin Polidocanol Foam (BPF) Stability – In Vitro Evidence for the Effectiveness of a Novel Sclerosant for Venous Malformations

Contact Info

Product

Resources

About